“Skin Clearance, Treatment Response Off-therapy, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis”, J of Skin, vol. 8, no. 6, p. s460, Nov. 2024, doi: 10.25251/skin.8.supp.460.